Download PDF
Dtsch Med Wochenschr 2020; 145(10): 682-686
DOI: 10.1055/a-1152-3469
Standpunkt

Renin-Angiotensin-System (RAS) und COVID-19 – Zur Verordnung von RAS-Blockern

Renin-Angiotensin-System (RAS) and COVID-19 – On The Prescription of RAS Blockers
Reinhold Kreutz
,
Engi Abd El-Hady Algharably
,
Detlev Ganten
,
Franz Messerli
› Further Information
Also available at
   Permissions and Reprints

Abstract

Twenty years ago, an enzyme homologous to the previously known angiotensin-converting enzyme (ACE) was identified, and subsequently named ACE2. In the renin-angiotensin system (RAS), ACE2 has counter-regulatory functions against the classical effector peptide angiotensin II, for example in blood pressure regulation and cardiovascular remodeling. However, ACE2 provides an initially unexpected interesting link between virology and cardiovascular medicine. That is, ACE2 represents the binding receptor for the cellular uptake of SARS-CoV and SARS-CoV-2 viruses. Thus, ACE2 is relevant for COVID-19. In this context, it was suspected that therapy with RAS blockers might promote transmission and complications of COVID-19 by upregulation of ACE2 expression. The aim of this short review is, to describe the link between the RAS, particularly ACE2, and COVID-19. Based on our analysis and evaluation of the available findings, we justify our conclusion: important drugs such as ACE inhibitors and angiotensin receptor blockers should continue to be prescribed according to guidelines to stable patients in the context of the COVID-19 pandemic.

In der Forschung zur SARS-Epidemie (2003) ergab sich schon damals unerwartet eine neue Verbindung zwischen Virologie und Herz-Kreislauf-Medizin – eine Erkenntnis, die wieder aktuell geworden ist. Denn inzwischen ist bekannt, dass ACE2 auch den Bindungsrezeptor für das neue Virus der COVID-19-Infektion, SARS-CoV-2, darstellt. Sind Medikamente wie ACEI und ARB nun riskant? Der Beitrag erläutert die Zusammenhänge und die Relevanz für den Praktiker.

Schlüsselwörter

Lungenschädigung - Hypertonieprävalenz - Infektiosität - zelluläre Serinprotease - Bindungsrezeptor

Key words

lung damage - prevalence of hypertension - infectivity - cellular serine protease - binding receptor


Publication History

Article published online:
22 April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Tipnis SR, Hooper NM, Hyde R. et al A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243 . doi:10.1074/jbc.M002615200
    CrossrefPubMedGoogle Scholar
  • 2 Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803 . doi:10.1152/physrev.00036.2005
    CrossrefPubMedGoogle Scholar
  • 3 Santos RAS, Sampaio WO, Alzamora AC. et al The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev 2018; 98: 505-553 . doi:10.1152/physrev.00023.2016
    CrossrefPubMedGoogle Scholar
  • 4 Arendse LB, Danser AHJ, Poglitsch M. et al Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev 2019; 71: 539-570 . doi:10.1124/pr.118.017129
    CrossrefPubMedGoogle Scholar
  • 5 Kreutz R, Algharably EA, Azizi M. et al Hypertension, the renin-angiotensin system and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. European Society of Hypertension COVID-19 Task Force Review of Evidence. Cardiovasc Res 2020; cvaa097. DOI: 10.1093/cvr/cvaa097
    PubMedGoogle Scholar
  • 6 Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 2008; 93: 543-548 . doi:10.1113/expphysiol.2007.040048
    CrossrefPubMedGoogle Scholar
  • 7 Stahlmann R, Lode H. Therapie von COVID-19 – erste klinische Studien mit verschiedenen Wirkstoffen. Dtsch Arztebl Int 2020; 117: 213-219 . doi:10.3238/arztebl.2020.0213
    PubMedGoogle Scholar
  • 8 Li W, Moore MJ, Vasilieva N. et al Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450-454 . doi:10.1038/nature02145
    Google Scholar
  • 9 Fauci AS, Lane HC, Redfield RR. Covid-19 – Navigating the Uncharted. N Engl J Med 2020; 382: 1268-1269 . doi:10.1056/NEJMe2002387
    CrossrefPubMedGoogle Scholar
  • 10 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; DOI: 10.1016/j.cell.2020.02.052.
    CrossrefPubMedGoogle Scholar
  • 11 Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension 2020; DOI: 10.1161/hypertensionaha.120.15082.
    CrossrefPubMedGoogle Scholar
  • 12 Forouzanfar MH, Liu P, Roth GA. et al Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. Jama 2017; 317: 165-182 . doi:10.1001/jama.2016.19043
    CrossrefPubMedGoogle Scholar
  • 13 Vaduganathan M, Vardeny O, Michel T. et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMsr2005760.
    CrossrefPubMedGoogle Scholar
  • 14 European Society of Hypertension, ESH. Im Internet (Stand 08.04.2020): www.eshonline.org/spotlights/esh-statement-on-covid-19/
    PubMed
  • 15 Deutsche Hochdruckliga, DHL. Im Internet (Stand: 08.04.2020): www.hochdruckliga.de/
    PubMed
  • 16 Williams B, Mancia G, Spiering W. et al 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens 2018; 36: 1953-2041 . doi:10.1097/hjh.0000000000001940
    CrossrefPubMedGoogle Scholar